690261-73-5

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(piperidin-4-yl)pyridine hydrochloride is used as a building block for the synthesis of various pharmaceuticals. Its unique structure allows it to be incorporated into the design of new drugs, potentially leading to the development of treatments for a variety of diseases.
Used in Agrochemical Production:
In the agrochemical industry, 3-(piperidin-4-yl)pyridine hydrochloride is used as an intermediate in the production of various agrochemicals. Its role in the synthesis of these compounds contributes to the development of effective solutions for agricultural applications.
Used in Fine Chemicals Industry:
3-(piperidin-4-yl)pyridine hydrochloride is utilized as a versatile intermediate in the fine chemicals industry. Its adaptability in chemical reactions makes it suitable for the creation of specialty chemicals used across different sectors.
Used in Medicinal Chemistry Research:
3-(piperidin-4-yl)pyridine hydrochloride is employed as a key component in medicinal chemistry research. It aids in the exploration and development of innovative drug candidates, which could address unmet medical needs and contribute to advancements in healthcare.

Upstream product

• 550371-77-2 tert-butyl 4-(pyridin-3-yl)piperidine-1-carboxylate 
• 690261-74-6 tert-butyl 5,6-dihydro-4-(pyridin-3-yl)pyridine-1(2H)-carboxylate 

Relevant academic research and scientific papers

Design, synthesis, and pharmacological evaluation of JDTic analogs to examine the significance of replacement of the 3-hydroxyphenyl group with pyridine or thiophene bioisosteres

The potent and selective KOR antagonist JDTic was derived from the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of pure opioid antagonists. In previous studies we reported that compounds that did not have a hydroxyl on the 3-hydroxyphenyl group and did not have methyl groups at the 3- and 4-position of the piperidine ring were still potent and selective KOR antagonists. In this study we report JDTic analogs 2, 3a–b, 4a–b, and 5, where the 3-hydroxyphenyl ring has been replaced by a 2-, 3-, or 4-pyridyl or 3-thienyl group and do not have the 3-methyl or 3,4-dimethyl groups, remain potent and selective KOR antagonists. Of these, (3R)-7-hydroxy-N-(1S)-2-methyl-[4-methyl-4-pyridine-3-yl-carboxamide (3b) had the best overall binding potency and selectivity in a [35S]GTPγS functional assay, with a Ke?=?0.18?nM at the KOR and 273- and 16,700-fold selectivity for the KOR relative to the MOR and DOR, respectively. Calculated physiochemical properties for 3b suggest that it will cross the blood–brain barrier.

HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I): (wherein R>12345610 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.